ACADIA Pharmaceuticals Inc. (ACAD)

Market Cap	3.75B
Revenue (ttm)	631.89M
Net Income (ttm)	-148.81M
Shares Out	164.18M
EPS (ttm)	-0.92
PE Ratio	n/a
Forward PE	16.43
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,142,050
Open	22.48
Previous Close	22.29
Day's Range	21.20 - 22.56
52-Week Range	14.45 - 33.99
Beta	0.59
Analysts	Buy
Price Target	31.44 (+47.05%)
Earnings Date	Nov 2, 2023

About ACAD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III AD...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2004
• Employees: 514
• Stock Exchange: NASDAQ
• Ticker Symbol: ACAD

Financial Performance

In 2022, ACAD's revenue was $517.24 million, an increase of 6.83% compared to the previous year's $484.15 million. Losses were -$215.98 million, 28.7% more than in 2021.

Analyst Forecast

According to 16 analysts, the average rating for ACAD stock is "Buy." The 12-month stock price forecast is $31.44, which is an increase of 47.05% from the latest price.

Price Target

$31.44

(47.05% upside)

Analyst Consensus: Buy